Women’s health has long remained one of the most underrepresented areas in medical research, leaving millions of patients without accurate diagnoses or personalised treatment for common conditions. Vaginal infections, fertility concerns, and menopause related symptoms are often misunderstood, with conventional diagnostic methods providing only limited insight into the underlying causes. Advances in genomics and microbiome science are now opening new possibilities for precision medicine, allowing clinicians to better understand the complex ecosystem that influences women’s health. UK founded healthtech company Juno Bio is helping drive this transformation and has now secured new funding while opening a dedicated sequencing laboratory designed specifically for women’s health.
Juno Bio has raised $3.8 million in funding from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.
Alongside the investment, the company has opened its first sequencing laboratory in Oakland, California, representing an important milestone in expanding access to clinically relevant microbiome testing for women.
The new capital will support continued platform development, scientific research, and broader access to precision diagnostics.
Advancing Precision Women’s Healthcare
Founded to address long standing gaps in women’s healthcare, Juno Bio focuses on precision vaginal microbiome testing powered by advanced sequencing technologies and multiomics research.
The company has spent several years developing scientific infrastructure designed to provide clinicians with a more detailed understanding of vaginal health than conventional diagnostic methods can offer.
Its approach combines advanced laboratory testing with clinically actionable insights, helping healthcare providers better understand conditions that are frequently overlooked, misunderstood, or misdiagnosed.
The company believes precision microbiome analysis can significantly improve decision making across women’s healthcare.
Opening a Dedicated Sequencing Laboratory
A major milestone in the company’s growth is the launch of its first dedicated sequencing laboratory built entirely around women’s health.
Located in Oakland, California, the facility enables Juno Bio to process tests within its own Clinical Laboratory Improvement Amendments certified laboratory.
The laboratory strengthens the company’s ability to deliver consistent, high quality testing while supporting future research and product development.
Bringing sequencing capabilities in house also allows the company to continue expanding one of the world’s largest repositories of vaginal microbiome data.
This growing database supports both clinical care and ongoing scientific discovery.
A More Comprehensive View of Vaginal Health
Juno Bio’s latest clinically focused test provides a significantly broader assessment of vaginal health than many traditional diagnostic approaches.
Using next generation sequencing, the platform analyses approximately 10,000 different bacteria and fungi together with four common sexually transmitted infections.
Rather than focusing on only a limited number of pathogens, the system examines the wider vaginal microbiome to provide a more complete understanding of microbial balance and overall health.
The platform can help identify microbial patterns associated with bacterial vaginosis, yeast infections, aerobic vaginitis, cytolytic vaginosis, estrogen related changes, and other conditions that may influence patient care.
When combined with clinical assessment and reported symptoms, these insights support more personalised treatment decisions.
Building a Clinical Platform
Since launching its original wellness test, Juno Bio has sold more than 20,000 tests through organic growth.
The company has since evolved into a broader clinical platform supporting healthcare providers through laboratory services, pharmaceutical research collaborations, telehealth integration, pharmacy partnerships, and an expanding medical advisory network.
This integrated approach allows the company to combine diagnostics, research, and patient care within a single ecosystem focused exclusively on women’s health.
Its growing scientific infrastructure also supports continued development of future diagnostic solutions.
Closing the Women’s Health Gap
According to company data, many women seeking care for vaginal health concerns experience inaccurate or incomplete diagnoses before receiving appropriate treatment.
Conventional testing may overlook co infections and other microbiome related factors that influence symptoms and treatment outcomes.
By providing more detailed microbiome insights, Juno Bio aims to improve diagnostic accuracy while helping clinicians deliver more personalised care.
With fresh funding, expanded laboratory capabilities, and growing adoption of precision microbiome testing, the company is positioning itself to help redefine standards of care for women’s health. As interest in personalised medicine continues to grow, Juno Bio aims to provide healthcare professionals with deeper scientific insights that support better clinical decisions while improving outcomes for women worldwide.